ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

FAB Fusion Antibodies Plc

3.45
0.10 (2.99%)
13 Jun 2024 - Closed
Delayed by 15 minutes
Fusion Antibodies Investors - FAB

Fusion Antibodies Investors - FAB

Share Name Share Symbol Market Stock Type
Fusion Antibodies Plc FAB London Ordinary Share
  Price Change Price Change % Share Price Last Trade
0.10 2.99% 3.45 10:29:47
Open Price Low Price High Price Close Price Previous Close
3.35 3.35 3.45 3.45 3.35
more quote information »
Industry Sector
PHARMACEUTICALS & BIOTECHNOLOGY

Top Investor Posts

Top Posts
Posted at 04/6/2024 15:30 by gtc1508
hxxps://youtu.be/39NYX6tWW0M?feature=shared

Investor presentation
Posted at 28/5/2024 12:29 by soultrading
Mayfair investor presentation tomorrow evening,
Posted at 20/5/2024 10:57 by gtc1508
Fusion’s market capitalisation is £3.3m, suggesting an EV of £2.1m, based on year £1.2m end cash. We consider this to represent an interesting special situation geared to the success of Fusion’s recovery plan, where almost no value is currently being ascribed to its class leading antibody discovery technologies. This unusual situation has arisen as a result of the steep decline in revenue Fusion experienced in H2 FY23 that extended into FY24.

Given there is evidence of a turnaround in its fortunes and helped by an improved funding environment for biotech generally and its order book is now on an upward trajectory, our investment thesis is that investors will start to recognise the value inherent in Fusion’s class leading antibody discovery technology. To highlight this, we would draw attention to the valuation of Absci (Nasdaq: ABSI), an albeit much-larger US/Canadian-based firm that has an AI-led approach to antibody drug design. This company has a market capitalisation of $535m and cash of $72m, so has an EV of $463m.
Posted at 16/5/2024 18:12 by gtc1508
Investor presentation link
Posted at 15/5/2024 16:36 by bobaxe1
Investor meet company presentation tomorrow 11am
Posted at 07/5/2024 10:24 by troutisout
Good interview.
Rather than wait until the new traction is proven, those investors looking for maximum reward, must be looking at the current price and thinking about adding...
Posted at 10/1/2024 18:13 by cumnor
Yea, question is does management really have the expertise and clout to sell the brand to big investors-not penny punters. Should be an easy sell in reality-even getting the NCI in the US to show a remote interest in their antibody library is some feat one typically underappreciated by gormless UK II analysts who don't know their ars..from their elbows, and confirms the science side of things is worthwhile.
Persuading IIs that a single antibody with prospects (look at GSKs deal for early phase 2 respiratory AB they paid a billion + for the right to develop-ex China-which hasn't even been approved for clinical use yet to give one an idea of the scale and potential here. I'm afraid mgmt don't seem up to it, especially if they have to resort to Proactive to sell the story for funds.
Posted at 08/12/2023 10:06 by jaknife
luckyabbeygale,

Well done on making a quick profit on a scalp trade.

You appear to be referring to this post:



==================================
luckyabbeygale,

"I missed the rise and was worried the sells start coming again. Therefore I only bought 200 pp at 6p and now I wish I bought a lot more."

You'll get the chance to buy a lot more at a lot lower, the accounts note that they expect to place in Q1.

JakNife
==================================

This comment was based on the words in GDR's accounts:

"The Group and Company does not currently have sufficient cash resources to continue as a going concern during the forecast period due to the time expected to be needed to gain commercial traction in its revenues. Therefore, the Company will need to raise further equity, or other funding, in early 2024 in order to continue as a going concern. The forecasts prepared by the Directors include a plan to raise additional funds from equity investors or debt providers in early 2024 to allow the Company to continue as a going concern." [my bold]

see:

Q1 is a period of time that starts on 1 Jan 2024 and ends on 31 March 2024. I will entertain complaints about my post above at the end of Q1. In the meantime I wish you a joyous Christmas!

JakNife
Posted at 07/12/2023 13:04 by bones698
Must admit unless they manage to sign some decent deals they will be raising cash in the next few months for sure . Even with a big contract which hasn't arrived and is never guaranteed until it's signed the cash position is precarious and the longer they leave it and closer they get to running out of cash the worse the raise will be for investors ..
The mkt cap is minimal just over a million leaks anything decent could see this rocket but the odds of that are slim and it's this price for a reason.
I'll wait for news and financing before even thinking of investing here it's just very very high risk
Posted at 06/12/2023 17:18 by clocktower
LOL daniel - his warnings were spot on when the nasty Paul Warwick was trying desperately to shore up his position by ramping this and saying he was getting his friends to buy even when it bounced to 95p, as I think he must have swallowed hook sink and line what the previous Board of Directors feed him.

I never like to see Private Investors make losses but in his case I have no sympathy at all, due to his actions.

I have not followed it closely since they did the raise at the huge discount after the first profitable bounce, while warning this share is a dog.

Still if you to have taken the bait, I hope you will not get hurt if and when the hook bites.

Your Recent History

Delayed Upgrade Clock